Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells

被引:53
作者
Albitar, Lina
Pickett, Gavin
Morgan, Marilee
Davies, Suzy
Leslie, Kimberly K.
机构
[1] Univ New Mexico, Hlth Sci Ctr, Canc Res & Treatment Ctr, Dept Obstet & Gynecol, Albuquerque, NM 87131 USA
[2] Univ New Mexico, Hlth Sci Ctr, Canc Res & Treatment Ctr, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA
[3] Univ New Mexico, Hlth Sci Ctr, KUGR Microarrays & Genom Facil, Albuquerque, NM 87131 USA
关键词
endometrial cancer; Ishikawa H cells; Hec50co cells; tumor suppressor; RB1; PTEN; p53; RBL1; RBL2; PROGESTERONE-RECEPTOR; RETINOBLASTOMA GENE; SEROUS CARCINOMA; PATHWAY; EXPRESSION; MUTATIONS; ISOFORM; PROTEIN; P53; OVEREXPRESSION;
D O I
10.1016/j.ygyno.2007.02.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Endometrial cancer models are critical to the advancement of investigation, and Ishikawa H and Hec50co cells have been used as research tools. The purpose of these studies is to verify the degree to which these commonly used cell models share the molecular characteristics of the two major in vivo endometrial cancer subtypes, I and II. Methods. The studies reported include an analysis of pathologic features, tumor suppressor mutations, detailed karyotyping, and cell cycle regulation. Results. Ishikawa H cells are hormone responsive and have lost PTEN expression. In addition they have lost RBI expression due to a deletion in exon 9. Hec50co cells have lost p53 expression due to a deletion at the junction of exon 6 and intron 6-7. Compared to Ishikawa H cells, Hec50co cells harbor many more chromosomal rearrangements (29 versus seven), and the doubling time is more rapid. The percent of cells in each phase of the cell cycle is reported and linked to cell cycle regulators. Conclusion. We present extensive data indicating that Ishikawa H cells are excellent models for type I endometrial cancers, and Hec5Oco cells faithfully replicate the molecular characteristics of type II endometiial cancers. These studies allow testing of new therapeutic regimens using appropriate cell models. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:52 / 64
页数:13
相关论文
共 33 条
[1]   Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein [J].
Armes, Jane E. ;
Lourie, Rohan ;
de Silva, Melanie ;
Stamaratis, Georgia ;
Boyd, Alison ;
Kumar, Beena ;
Price, Gareth ;
Hyde, Simon ;
Allen, David ;
Grant, Peter ;
Venter, Deon J. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2005, 24 (04) :363-368
[2]   2 PATHOGENETIC TYPES OF ENDOMETRIAL CARCINOMA [J].
BOKHMAN, JV .
GYNECOLOGIC ONCOLOGY, 1983, 15 (01) :10-17
[3]   p107 and p130: Versatile proteins with interesting pockets [J].
Classon, M ;
Dyson, N .
EXPERIMENTAL CELL RESEARCH, 2001, 264 (01) :135-147
[4]  
Dai DH, 2005, MOL CANCER THER, V4, P169
[5]   Immunomodulatory and transcriptional effects of progesterone through progesterone A and B receptors in Hec50co poorly differentiated endometrial cancer cells [J].
Davies, S ;
Dai, DH ;
Wolf, DM ;
Leslie, KK .
JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 2004, 11 (07) :494-499
[6]   Cancer risk associated with germline DNA mismatch repair gene mutations [J].
Dunlop, MG ;
Farrington, SM ;
Carothers, AD ;
Wyllie, AH ;
Sharp, L ;
Burn, J ;
Liu, B ;
Kinzler, KW ;
Vogelstein, B .
HUMAN MOLECULAR GENETICS, 1997, 6 (01) :105-110
[7]   Focus on endometrial and cervical cancer [J].
Ellenson, LH ;
Wu, TC .
CANCER CELL, 2004, 5 (06) :533-538
[8]  
ENOMOTO T, 1991, CANCER RES, V51, P5308
[9]   Immunohistochemical profile of endometrial adenocarcinoma: A study of 61 cases and review of the literature [J].
Kounelis, S ;
Kapranos, N ;
Kouri, E ;
Coppola, D ;
Papadaki, H ;
Jones, MW .
MODERN PATHOLOGY, 2000, 13 (04) :379-388
[10]  
Kumar NS, 1998, CANCER RES, V58, P1860